Journal of the National Cancer Institute

publication venue for

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. 2018
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. 1991
Comprehensive analysis of germline drivers in endometrial cancer.. 115. 2023
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials.. 115. 2023
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.. 114. 2022
Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening.. 114. 2022
Digital Health Applications in Oncology: An Opportunity to Seize.. 114. 2022
A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers.. 113. 2021
Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.. 113. 2021
Parallels Between the Antiviral State and the Irradiated State.. 113. 2021
Central Adiposity and Subsequent Risk of Breast Cancer by Menopause Status.. 113. 2021
Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19.. 113. 2021
Early-Life Body Adiposity and the Breast Tumor Transcriptome.. 113. 2021
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.. 113. 2021
Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.. 113. 2021
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.. 113. 2021
Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.. 113. 2021
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.. 113. 2021
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.. 113. 2021
Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.. 112. 2020
Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data.. 112. 2020
A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women.. 112. 2020
Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study.. 112. 2020
Mammographic Density Change and Risk of Breast Cancer.. 112. 2020
Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.. 111. 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.. 111. 2019
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.. 111. 2019
The Genomic Landscape of Mucinous Breast Cancer.. 111. 2019
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.. 111. 2019
Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.. 111. 2019
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.. 111. 2019
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.. 111. 2019
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.. 111. 2019
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.. 110. 2018
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.. 110. 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.. 110. 2018
The Future of Radiobiology.. 110. 2018
Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.. 109. 2017
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.. 109. 2017
Role of RPL39 in Metaplastic Breast Cancer.. 109. 2016
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.. 109. 2016
General Biomarker Recommendations for Lymphoma.. 108. 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.. 108. 2016
Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways.. 108. 2016
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.. 108. 2015
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.. 108. 2015
Melanoma Thickness and Survival Trends in the United States, 1989 to 2009.. 108. 2015
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.. 107. 2015
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.. 107. 2015
Marketing of personalized cancer care on the web: an analysis of Internet websites.. 107. 2015
Primary tumor location as a prognostic factor in metastatic colorectal cancer.. 107. 2015
Identification of metastasis-suppressive microRNAs in primary melanoma.. 107. 2015
Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers.. 107. 2014
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.. 107. 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.. 106. 2014
Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.. 106. 2014
Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment.. 106. 2014
The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study.. 106. 2014
Realizing the potential of plasma genotyping in an age of genotype-directed therapies.. 106. 2014
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).. 106. 2014
Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.. 106. 2014
Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.. 106. 2014
Prostate cancer mortality in areas with high and low prostate cancer incidence.. 106. 2014
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.. 106. 2014
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.. 106. 2014
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.. 106. 2013
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.. 105. 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.. 105. 2013
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.. 105. 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.. 105. 2013
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.. 105. 2013
Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk.. 105. 2013
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.. 105. 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. 105. 2013
Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.. 105. 2012
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.. 104. 2012
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.. 104. 2012
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.. 104. 2012
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.. 104. 2012
A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.. 104. 2012
Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.. 104. 2012
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust.. 104. 2012
Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma.. 103. 2011
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.. 103. 2011
Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.. 103. 2011
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion.. 103. 2011
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.. 103. 2011
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.. 103. 2011
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.. 103. 2010
Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study.. 102. 2010
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.. 102. 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.. 102. 2010
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.. 102. 2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.. 102. 2010
Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves.. 102. 2010
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.. 102. 2009
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.. 101. 2009
Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients.. 101. 2009
Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study.. 101. 2009
Cause-specific mortality in long-term survivors of retinoblastoma.. 101. 2009
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.. 101. 2009
Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.. 101. 2009
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.. 101. 2009
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.. 100. 2008
Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis.. 100. 2008
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. 100. 2008
Frequent p16-independent inactivation of p14ARF in human melanoma.. 100. 2008
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.. 100. 2008
Comparison of estrogen receptor results from pathology reports with results from central laboratory testing.. 100. 2008
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.. 100. 2008
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.. 100. 2007
Projecting individualized absolute invasive breast cancer risk in African American women.. 99. 2007
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.. 99. 2007
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.. 99. 2007
Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.. 99. 2007
The surgical learning curve for prostate cancer control after radical prostatectomy.. 99. 2007
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.. 99. 2007
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.. 99. 2007
When you look matters: the effect of assessment schedule on progression-free survival.. 99. 2007
Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.. 99. 2007
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.. 98. 2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.. 98. 2006
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.. 98. 2006
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.. 98. 2006
Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.. 98. 2006
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.. 98. 2006
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.. 97. 2005
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.. 97. 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.. 97. 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.. 97. 2005
Importance of communication between producers and consumers of publicly available experimental data.. 97. 2005
Lymph node evaluation in colorectal cancer patients: a population-based study.. 97. 2005
Ductal lavage findings in women with known breast cancer undergoing mastectomy.. 96. 2004
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.. 96. 2004
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.. 96. 2004
Determinants of BRAF mutations in primary melanomas.. 95. 2003
Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients.. 95. 2003
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.. 95. 2003
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.. 95. 2003
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome.. 95. 2003
Adherence to surveillance among patients with superficial bladder cancer.. 95. 2003
Variations in lung cancer risk among smokers.. 95. 2003
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.. 94. 2002
On the use of familial aggregation in population-based case probands for calculating penetrance.. 94. 2002
Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia.. 93. 2001
Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial.. 93. 2001
Age and adjuvant chemotherapy use after surgery for stage III colon cancer.. 93. 2001
Detecting colorectal cancer in stool with the use of multiple genetic targets.. 93. 2001
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.. 93. 2001
Human papillomavirus type 16 variants and risk of cervical cancer.. 93. 2001
Hereditary retinoblastoma and risk of lung cancer.. 92. 2000
Her-2-neu expression and progression toward androgen independence in human prostate cancer.. 92. 2000
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma.. 92. 2000
Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting.. 92. 2000
Association of angiogenesis in lymph node metastases with outcome of breast cancer.. 92. 2000
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.. 92. 2000
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.. 91. 1999
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.. 91. 1999
Telomerase activity in germ cell cancers and mature teratomas.. 91. 1999
Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization.. 91. 1999
Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin.. 91. 1999
p53 and genetic susceptibility to cervical cancer.. 91. 1999
Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells.. 91. 1999
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.. 91. 1999
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.. 91. 1999
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.. 90. 1998
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.. 90. 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.. 90. 1998
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.. 90. 1998
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.. 90. 1998
Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer.. 90. 1998
High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage.. 89. 1997
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.. 89. 1997
Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.. 89. 1997
Hereditary retinoblastoma, lipoma, and second primary cancers.. 89. 1997
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.. 88. 1996
Screening for cutaneous melanoma by skin self-examination.. 88. 1996
Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma.. 87. 1995
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.. 87. 1995
Deletion of the p16 and p15 genes in human bladder tumors.. 87. 1995
Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.. 87. 1995
Lung cancer after Hodgkin's disease.. 87. 1995
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.. 87. 1995
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.. 87. 1995
Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.. 87. 1995
Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases.. 87. 1995
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.. 86. 1994
Altered patterns of MDM2 and TP53 expression in human bladder cancer.. 86. 1994
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.. 86. 1994
Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas.. 86. 1994
Clinical relevance of the i(12p) marker chromosome in germ cell tumors.. 86. 1994
Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course.. 86. 1994
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow.. 85. 1993
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.. 85. 1993
Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.. 85. 1993
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival.. 85. 1993
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.. 85. 1993
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.. 85. 1993
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.. 85. 1993
Mortality from second tumors among long-term survivors of retinoblastoma.. 85. 1993
Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?. 85. 1993
Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.. 85. 1993
Protein kinase C: a novel target for inhibiting gastric cancer cell invasion.. 85. 1993
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.. 85. 1993
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.. 85. 1993
Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.. 84. 1992
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.. 84. 1992
Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine.. 84. 1992
Dose-ranging trial of zacopride: the emetic antiemetic?. 84. 1992
Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice.. 83. 1991
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.. 83. 1991
Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid.. 82. 1990
Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma.. 82. 1990
Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors.. 82. 1990
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors.. 81. 1989
Model predicting survival in stage I melanoma based on tumor progression.. 81. 1989
Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine.. 81. 1989
In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.. 81. 1989
Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody.. 81. 1989
Publication bias and dissemination of clinical research.. 81. 1989
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.. 81. 1989
Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.. 77. 1986
Adhesion, chemotaxis, and aggregation of Walker carcinosarcoma cells in response to products of resorbing bone.. 74. 1985
Rate of disease progression in breast cancer: a clinical estimate of prognosis within nodal and anatomic stages.. 72. 1984
Protein A-independent tumoricidal responses in dogs after extracorporeal perfusion of plasma over Staphylococcus aureus.. 70. 1983
Subpopulations of human T-lymphocytes. XIX. T-cells and T-cells with receptors for IgMFc (T mu), IgGFc (T gamma), or IgAFc (T alpha) in the peripheral blood and regional lymph nodes of patients with untreated breast cancer.. 69. 1982
Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women.. 67. 1981
Glucose disposal and gluconeogenesis from alanine in tumor-bearing Fischer 344 rats.. 66. 1981
Breast cancer and reproductive history from genealogical data.. 64. 1980
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers.. 64. 1980
Glucose turnover and gluconeogenesis during hypocaloric glucose infusion in tumor-bearing F344 male rats.. 64. 1980
Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor.. 64. 1980
Elution of tumor-directed antibody from kidneys of mammary tumor-bearing mice.. 59. 1977
Growth curve of an experimental solid tumor following radiotherapy.. 58. 1977
Cytotoxic reactions of murine lymphoid cells studied with a tritiated proline microcytotoxicity test.. 54. 1975
Suspension culture of a pigment-producing cell line derived from a human malignant melanoma.. 41. 1968
BEHAVIOR OF P388 MOUSE LEUKEMIA IN THE CHICK EMBRYO AND HATCHED CHICK.. 32. 1964
Scottish Health Executive revamps cancer care.. 93. 2001
Medicare coverage group assesses effectiveness of new technologies.. 93. 2001
Despite efficacy of prophylactic mastectomy, procedure finds few enthusiasts.. 93. 2001
French National Ad Hoc Committee strongly resists prophylactic mastectomy.. 93. 2001
Prophylactic oophorectomy in the genome age: balancing new data against uncertainties.. 93. 2001
Panel examines impact of public figures on cancer awareness.. 93. 2001
Avalanche of direct-to-consumer drug marketing brings new questions.. 92. 2000
Response to Takahashi. 2022
Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. 2020
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. 2019
Response. 2016
Response. 2014
Re: A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. 2012
Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. 2011
Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. 2011
Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. 2011
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. 2009
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. 2009
Re: When you look matters: the effect of assessment schedule on progression-free survival. 2008
Re: Trends in radical prostatectomy rates. 2007
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. 2007
Re: Ductal lavage findings in women with known breast cancer undergoing mastectomy. 2005
Re: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. 2004
Re: All-cause mortality in randomized trials of cancer screening. 2002
Re: Gene therapy strategies for tumor antiangiogenesis. 1998
Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. 1997
Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. 1996
Transferrin receptor expression in testis cancer. 1994
Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. 1992
Retrospective review of neoadjuvant chemotherapy for osteogenic sarcoma. 1992
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. 2014
Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. 2004
Addressing health-related quality of life inequities in cancer: where do we go from here?. 115. 2023
Minding the Gap: Cancer-Related Survival Disparities in Adolescent and Young Adult Survivors.. 114. 2022
Addressing Overtreatment in DCIS: What Should Physicians Do Now?. 107. 2015
New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.. 107. 2015
Opportunities-and hard work-ahead.. 107. 2014
How to get from here to there: tracking down invasive glioma cells.. 106. 2014
Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?. 106. 2014
Justifying the choice of endpoints for clinical trials.. 105. 2013
Epoetin alfa: to give or not to give.. 105. 2013
Margins in ductal carcinoma in situ: is bigger really better?. 104. 2012
Time for a new era in outcomes reporting for breast reconstruction.. 103. 2010
Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility.. 101. 2009
Quality pancreatic cancer care: it's still mostly about volume.. 101. 2009
The taxane limbo: how low can we go?. 100. 2008
18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.. 99. 2007
Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.. 99. 2007
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer.. 99. 2007
BRCA mutation frequency and penetrance: new data, old debate.. 98. 2006
Assessing breast cancer risk: evolution of the Gail Model.. 98. 2006
Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer.. 97. 2005
Reflections on the landmark studies of beta-carotene supplementation.. 96. 2004
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. 96. 2004
The certainties and the uncertainties of ductal carcinoma in situ.. 96. 2004
Attribution of deaths following cancer treatment.. 94. 2002
Polyomavirus and medulloblastoma: a smoking gun or guilt by association?. 94. 2002
Ovarian tumors of low malignant potential: Can molecular biology solve this enigma?. 93. 2001
HER2 in prostate cancer--a viable target or innocent bystander?. 92. 2000
Tubulin/microtubules: still a promising target for new chemotherapeutic agents.. 92. 2000
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer.. 91. 1999
Cigarette smoking and esophageal and gastric cardia adenocarcinoma.. 89. 1997
Suramin: here to stay!?. 85. 1993
Phase II trials in small-cell lung cancer: shouldn't we be doing better?. 84. 1992
Active cancer therapy combining 13-cis-retinoic acid with interferon-alpha.. 84. 1992
Dietary factors in colorectal cancer and their possible effects on earlier stages of hyperproliferation and adenoma formation.. 84. 1992
Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy.. 83. 1991
There is more to hemorrhagic necrosis than tumor necrosis factor.. 83. 1991
Grade Migration of Prostate Cancer in the United States During the Last Decade. 2022
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. 2020
Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. 2020
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. 2017
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. 2016
Recommendations for Clinical Trial Development in Follicular Lymphoma. 2016
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. 2016
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. 2016
Migraine and breast cancer risk: a prospective cohort study and meta-analysis. 2014
Mammographic density phenotypes and risk of breast cancer: a meta-analysis. 2014
Better therapeutic trials in ovarian cancer. 2014
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. 2014
Combining radiotherapy and cancer immunotherapy: a paradigm shift. 2013
Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. 2012
Second malignant neoplasms and cardiovascular disease following radiotherapy. 2012
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. 2012
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 2011
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. 2010
Improved endpoints for cancer immunotherapy trials. 2010
Testicular cancer survivorship: research strategies and recommendations. 2010
Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? 2008
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. 2006
Cetuximab therapy and symptomatic hypomagnesemia. 2005
Developing inhibitors of the epidermal growth factor receptor for cancer treatment. 2003
Development of investigational radiation modifiers. 2003
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. 2001
Development of matrix metalloproteinase inhibitors in cancer therapy. 2001
Participation in the cooperative family registry for breast cancer studies: issues of informed consent. 2000
Gene therapy strategies for tumor antiangiogenesis. 1998
Clinical trials in relapsed prostate cancer: defining the target. 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. 1996
Local control following breast-conserving surgery for invasive cancer: results of clinical trials. 1995
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. 1992
Improved tumor targeting with radiolabeled, recombinant, single-chain, antigen-binding protein. 1990

VIVO Weill Cornell Medical College

Journal of the National Cancer Institute Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)